Navepegritide not checked

Ascendis Pharma A/S

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
6 active
8 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Administered as two separate SC injections. Treatment duration of up to 52 weeks of navepegritide and placebo for lonapegsomatropin followed by 52 weeks of navepegritide and lonapegsomatropin.”In the company’s words, NCT07924059 on ClinicalTrials.gov
Tested for
Achondroplasia (5 trials), Hypochondroplasia
Main trialPhase 3
“This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.”In the company’s words, NCT07924059 on ClinicalTrials.gov
Other names
TransCon CNP

Other drugs for Achondroplasia

All 8 drugs for Achondroplasia

Coming up5

Changes2

Last 90 days

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Sep 2028 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Phase 3Not yet recruiting Oct 2028 A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia
Phase 2/3Enrolling by invitation Jan 2039 A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
Phase 2Active, not recruiting 14 Nov 2025 A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Phase 2Active, not recruiting Sep 2027 A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Phase 2Recruiting Dec 2027 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Phase 2/3Completed 9 Aug 2024 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Phase 2Completed 27 Sep 2022 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Navepegritide

Following is part of Solo: you see every change to Navepegritide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in